While the FDA came out on top over the EMA in terms of approvals, both agencies greenlighted fewer new drugs than in 2024.

The UK is now the first nation to approve the maximum dose 7.2mg Wegovy regimen, which will be used to treat obesity.

Public markets are showing early signs of reopening, as Q4 2025 saw a 157% increase in IPO deal volume compared to Q4 2024.

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

InterAx Biotech has entered into a strategic research collaboration and licensing agreement with Alveus Therapeutics to ...

Agenus has completed a $141m strategic collaboration with Zydus Lifesciences to accelerate the global development and ...

Novavax’s president and CEO reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond at a ...

Enanta’s portfolio of RSV replication inhibitors with potential for first-in-disease and best-in-disease treatment.

Eli Lilly highlighted 2025 as the rollout year for obesity drugs, with Mounjaro at the forefront of its weight-loss portfolio ...

The funding aims to encourage innovation in Europe amid concerns that innovation across the continent is lagging behind China ...

Jazz Pharmaceuticals has sold a priority review voucher (PRV) for $200m, suggesting the uptick in market prices for the ...

To thrive beyond rare disease, cell and gene therapy developers must scale-up manufacturing and commercialisation.